WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124819
CAS#: 1919043-65-4
Description: PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
Hodoodo Cat#: H124819
Name: Parpi
CAS#: 1919043-65-4
Chemical Formula: C27H22F2N4O3
Exact Mass: 488.17
Molecular Weight: 488.490
Elemental Analysis: C, 66.39; H, 4.54; F, 7.78; N, 11.47; O, 9.83
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Parpi; OWV057OPZ3; UNII-OWV057OPZ3; 1919043-65-4
IUPAC/Chemical Name: 4-[[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenyl]methyl]-2H-phthalazin-1-one
InChi Key: LTZZZXXIKHHTMO-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H22F2N4O3/c28-19-8-6-18(7-9-19)26(35)32-11-13-33(14-12-32)27(36)22-15-17(5-10-23(22)29)16-24-20-3-1-2-4-21(20)25(34)31-30-24/h1-10,15H,11-14,16H2,(H,31,34)
SMILES Code: O=C1NN=C(CC2=CC=C(F)C(C(N3CCN(C(C4=CC=C(F)C=C4)=O)CC3)=O)=C2)C5=C1C=CC=C5
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 488.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi
resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resist
Updat. 2021 Mar;55:100744. doi: 10.1016/j.drup.2021.100744. Epub 2021 Jan 16.
PMID: 33551306.
2: Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic.
Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub
2017 Mar 16. PMID: 28302823; PMCID: PMC6175050.
3: Washington CR, Moore KN. Resistance to Poly (ADP-Ribose) Polymerase
Inhibitors (PARPi): Mechanisms and Potential to Reverse. Curr Oncol Rep. 2022
Dec;24(12):1685-1693. doi: 10.1007/s11912-022-01337-6. Epub 2022 Nov 8. PMID:
36346509.
4: Shen D, Luo J, Chen L, Ma W, Mao X, Zhang Y, Zheng J, Wang Y, Wan J, Wang S,
Ouyang J, Yi H, Liu D, Huang W, Zhang W, Liu Z, McLeod HL, He Y. PARPi treatment
enhances radiotherapy-induced ferroptosis and antitumor immune responses via the
cGAS signaling pathway in colorectal cancer. Cancer Lett. 2022 Dec 1;550:215919.
doi: 10.1016/j.canlet.2022.215919. Epub 2022 Sep 16. PMID: 36116741.
5: Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic
Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res. 2019
Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.
PMID: 30482774; PMCID: PMC6588002.
